Morehouse School of Medicine is a private co-educational medical school in Atlanta, Georgia. Originally a part of Morehouse College, the school became independent in 1981. The school abbreviates its name with its initials "MSM.
Objective: Smartwatches with photoplethysmographic (PPG) sensors are ideal for early atrial fibrillation (AF) detection through continuous monitoring. However, prior deep learning was limited either to controlled environments, to minimize motion artifacts, or to short duration data collection. Additionally, premature atrial/ventricular contractions (PAC/PVC), which often confound AF detection algorithms, remains understudied due to limited datasets. Current state-of-the-art methods achieve only 75% sensitivity for PAC/PVC class on minimally motion artifact corrupted PPG data, despite showing 97% AF detection accuracy. Methods: We addressed the above limitations using data from the recently completed NIH-funded Pulsewatch clinical trial which collected over two weeks of smartwatch PPG data from 106 subjects. Our computationally efficient 1D bi-directional Gated Recurrent Unit deep learning model incorporated multi-modal inputs (1D PPG, accelerometer, and heart rate data) to classify normal sinus rhythm, AF, and PAC/PVC. Results: Our model achieved an unprecedented 83% sensitivity for PAC/PVC detection while maintaining a high accuracy of 97.31% for AF detection, outperforming the best retrained state-of-the-art model by 20.81% and 2.55%, respectively. It was also 14 times more computationally efficient and 2.7 times faster. Testing on two external PPG datasets collected with a different smartwatch and a fingertip PPG sensor, our model demonstrated better generalizability with macro-averaged AUROC values of 96.22% and 94.17%, respectively. Conclusion: A light-weight multimodal input deep learning model can accurately distinguish PAC/PVC from AF, reducing false positive detection of AF. Significance: Accurate AF and PAC/PVC detection with minimal false positive detection can enhance clinical and public acceptance of smartwatch-based AF monitoring.
Patients with cancer requiring surgery are at increased risk for depressive symptoms. However, prevalence and severity during the perioperative period are poorly characterized. This study systematically reviewed the perioperative prevalence of clinically significant depression and depressive symptom severity in patients with cancer, as measured by self-reported tools. A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using PubMed, EMBASE, and Scopus databases (searched to 15 December 2023). Clinical studies of patients with cancer undergoing surgery that measured depressive symptoms using a self-reported instrument were included. Study quality and bias were assessed using the Oxford Centre for Evidence-Based Medicine Levels of Evidence and Joanna Briggs Institute Critical Appraisal Checklist. Data extracted included study characteristics, as well as prevalence and severity of depression pre- and postoperatively. Data from 526 studies involving 103,075 surgical patients were included. The most common cancers were breast (32
BACKGROUND:UNITI Jr is a phase 3 study evaluating the efficacy, safety, and pharmacokinetics of ustekinumab, an interleukin-12/-23 antagonist, in pediatric patients with moderately to severely active Crohn's disease. Results from patients weighing at least 40 kg are reported. METHODS:Patients at least 40 kg and aged less than 18 years with a Pediatric Crohn's Disease Activity Index score of >30 received a single intravenous weight-tiered induction dose of ustekinumab. After 8 weeks, patients were randomized to subcutaneous ustekinumab 90 mg every 8 or 12 weeks. The primary endpoint was clinical remission at Week 8. Secondary endpoints included clinical response (Weeks 8, 52), endoscopic response (Weeks 16, 52), clinical remission, and corticosteroid-free remission (Week 52). RESULTS:Of 48 patients, median age was 15.0 years (interquartile range: 14.0-16.0). At Week 8, 52.1% (25/48) achieved clinical remission and 93.8% (45/48) achieved clinical response. At Week 16, 29.8% (14/47) achieved endoscopic response. Clinical remission at Week 52 was achieved in 15/25 (60.0%; every 12 weeks) and 10/23 (43.5%; every 8 weeks). Three patients (6.3%) discontinued ustekinumab between Weeks 8 and 52. Ustekinumab was safe and well-tolerated; adverse event rates were similar between groups. Immunogenicity was low; trough median (mean) steady-state serum ustekinumab concentrations following 8 weeks of dosing were 1.38 (2.08) to 1.74 (2.32) μg/mL and were comparable to levels in adult patients: 2.83 (2.05) μg/mL. CONCLUSIONS:Ustekinumab induction and maintenance therapy was effective and safe through 52 weeks in pediatric patients weighing at least 40 kg with moderately to severely active Crohn's disease. TRIAL REGISTRATION NUMBERS:NCT04673357.
Black and Hispanic communities have been historically marginalized in medicine including gastroenterology. It is widely appreciated that inflammatory bowel disease (IBD) impacts people of all races and ethnicities. Despite this recognition, there is a paucity of high-quality research investigating these disparities. The reasons for this paucity are multifactorial, and they require innovative solutions. An added dimension which may have an unanticipated compounding effect is a disproportionately low number of Black and Hispanic learners progressing through medical and healthcare education pathways. Continued and concerted engagement of all stakeholders including patients, learners, and practitioners is a key step toward addressing the steep knowledge gap in our understanding of IBD in Hispanic or Black individuals compared with White individuals. In this commentary, we highlight advances in the understanding of genetics in diverse populations and the impact on healthcare, discuss strategies to augment research participation among Black and Hispanic individuals, emphasize the importance of equity in IBD clinical practice and highlight exceptional organizations championing diversity in gastroenterology and IBD, focus on barriers to identifying and addressing disparities in IBD treatment across diverse populations, and finally, we briefly discuss the very limited existing literature on IBD in Indigenous populations in whom much less is known or understood.